Drug
Dky709
Dky709: highest development phase Phase 1, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| DKY709 NCT03891953 | Phase 1 | Carcinoma, Non-Small-Cell Lung |
Latest
No recent events.
Follow Dky709 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.